Cardinal Health (CAH) Stock: Buy, Sell, or Hold?
CAH - Cardinal Health, Inc.
$255.64
-1.82 (-0.71%)
▼
5d:
+0.76%
30d:
+15.53%
90d:
+12.11%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 05, 2026
13d
Get Alerted When CAH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CAH shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CAH shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$382.35
Based on 10.9% avg growth
INTRINSIC VALUE TODAY
$237.41
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CAH is currently trading at $255.64, which is considered extended relative to its 30-day fair value range of $222.79 to $246.14. From a valuation perspective, the stock is trading at a premium (Forward PE: 21.4) compared to its historical average (19.0). At these levels, the market is pricing in 4.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CAH is in a uptrend. The price is approaching resistance at $259.21. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CAH scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CAH is in a uptrend. The price is approaching resistance at $259.21. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CAH scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$222.79 -
$246.14
Company Quality Score
31/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
24.8%
Protect Your Profits
CAH is technically overbought (RSI 71). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($271.47)
- NEUTRAL: Market pricing in 4.0% annual earnings growth - fairly valued
- WARNING: Composite score 31/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$222.79 -
$246.14
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$233.88
Resistance Level
$259.21
Current Trend
Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.36
Wall Street Target
$271.47
(+5.4%)
Revenue Growth (YoY)
5.8%
Earnings Growth (YoY)
68.8%
Profit Margin
0.7%
Valuation Premium vs History
+4.0% premium
PE vs Historical
21.4 vs 19.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.0%
(market-implied from PE analysis)
1-Year Target
$267.76
(+4%)
2-Year Target
$278.47
(+8%)
3-Year Target
$289.61
(+13%)
3-Yr Target (if PE normalizes)
(PE: 21→19)
PE COMPRESSION
$257.64
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.4, Growth: 17.8%)
$421.26
(+64%)
Base:
(SPY PE: 19.9, Growth: 17.8%)
$391.72
(+52%)
Bear:
(PE: 16.9, Growth: 17.8%)
$332.96
(+29%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (35x PE), but valuation improves significantly next year (21x PE) as earnings recover.
Trailing PE: 34.95 | Current EPS (TTM): $7.37
Bull Case
$463.39
(+80%)
Analyst growth 63.6%, PE expands to 38.4
Base Case
$421.26
(+64%)
Market implied 63.6%, PE stable at 35.0
Bear Case
$175.13
(-32%)
Severe decline -20.0%, PE contracts to 29.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 22, 2026 4:12 PM ET
Data refreshes hourly during market hours. Next update: 5:12 PM
Data refreshes hourly during market hours. Next update: 5:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Distribution Stocks
Top-rated stocks in Medical Distribution by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
MCK
McKesson Corporation |
STRONG BUY
16 analysts |
$1001 | 36 SELL |
|
HSIC
Henry Schein Inc |
BUY
16 analysts |
$97 | 59 HOLD |
|
COR
Cencora Inc. |
STRONG BUY
14 analysts |
$368 | 34 SELL |
|
QIPT
Quipt Home Medical Corp |
STRONG BUY
5 analysts |
$4 | 52 HOLD |
|
OMI
Owens & Minor Inc |
HOLD
6 analysts |
$6 | 46 HOLD |
Advanced CAH Option Strategies
Professional options setups generated by AI based on today's CAH price and gamma walls.
